Regeneron's PANORAMA study for Eylea in Diabetic Retinopathy shows Promise

(c) PMLive

Regeneron Pharmaceuticals, Inc. announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy. Diabetic retinopathy, which affects about eight million people, is the result of microvascular damage to the blood vessels in the retina related to lack of blood sugar control in diabetic patients.

A Biomarker could predict response of intravitreal injections in Diabetic Macular Edema

(c) OMICS

Researchers at St. Michael’s Hospital have found an association with a biomarker from aqueous fluid in the eye that predicts which patients will respond best to current treatments for diabetic macular edema. Their findings suggest this biomarker may be not only a marker of disease severity and anatomic response but also a potential therapeutic target in DME, recognizing that in patients with DME, there is not always a direct correlation between anatomic and visual acuity response.

Muller cells a key cell in preventing age-related vision loss

(c) Duke

Duke researchers have pinpointed a new therapeutic target for macular degeneration. Clinical trials have shown that injection of human umbilical stem cells, or hUTC, into the retina helps preserve and restore vision in macular degeneration patients. However, the underlying mechanisms behind the therapy remain unknown. Their findings show that hUTC treatment preserves the function of a retinal cell called the Müller glia in rats with degenerative vision loss.

New Research demonstrates success with Gene Therapy for a form of Inherited Macular Degeneration

(c) UPenn News

Researchers from the University of Pennsylvania have developed a gene therapy that successfully treats a form of macular degeneration in a canine model. The work sets the stage for translating the findings into a human therapy for an inherited disease that results in a progressive loss of central vision and which is currently untreatable.

Clearside's CLS-TA achieves endpoints in Phase 3 PEACHTREE trial

(c) Retinal Physician

Clearside Biomedical, Inc. has announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis.

NEI/NIH launch clinical trial to study AMD progression

(c) NEI / NIH

A new clinical study led by the National Eye Institute (NEI), part of the National Institutes of Health, will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD). By using the latest technologies to visualize structures within the eye and measure their function, researchers hope to identify biomarkers of disease progression, well before it advances to late-stage disease and causes vision loss.

RG7716 improves visual acuity in subjects with Diabetic Macular Edema in a Phase 2 study

(c)Pharmacodia.com

Genentech announced results from the Phase II BOULEVARD study, which is evaluating subjects with vision loss from diabetic macular edema (DME), where treatment with intravitreal RG7716 was observed to be clinically meaningful and statistically significant in improvement of visual acuity gains compared with ranibizumab alone.